Boehringer Ingelheim Venture Fund — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
C-mo develops an automated wearable device that records and analyzes cough patterns in real-time for continuous patient monitoring.
Digital HealthHealthtechMedical DevicesCaparica, PT
Co-investorsNovalis BiotechPortugal Ventures
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsDelos CapitalVivo CapitalAMR Action FundKorea Investment PartnersLilly Asia VenturesMatrix Capital Management+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.